SHELTON, Conn.– PerkinElmer, a global leader in analytical solutions and specialized services for (bio)pharma, applied and food markets, today announced the acquisition of Project Farma, a subsidiary of Precision for Medicine. Project Farma is a leading life sciences consultancy focused on advancing technical operations from ideation through commercialization, offering project management, project controls, commissioning, qualification and validation, quality compliance and engineering consulting services. Terms of the acquisition were not disclosed.
“We are excited to welcome Project Farma’s highly skilled teams to PerkinElmer,” said Dirk Bontridder, CEO of PerkinElmer. “This acquisition expands the professional services offering of OneSource, our market-leading lab solutions business, and creates an even stronger solution offering for life sciences customers throughout the value chain. The addition further accelerates our mission to empower customers in delivering innovative therapies to market with greater speed and efficiency.”
Established in 2016, Project Farma is a patient-focused, global consultancy with a proven track record of planning, building, maintaining and retrofitting manufacturing facilities, capital expansions and technical operations in the life sciences industry. The company has a reputation as a leader in complex biologics, cell and gene therapies, radioligand and other novel modalities and in driving innovation and efficiency across the industry, helping clients bring groundbreaking therapies to market. Project Farma has supported large-scale initiatives, including helping design, build, scale and operate large Good Manufacturing Practices (GMP) facilities.
“Joining PerkinElmer’s OneSource business presents an incredible opportunity to accelerate our mission of advancing next-generation medicines,” said Anshul Mangal, co-founder and CEO of Project Farma. “Leveraging PerkinElmer’s global customer portfolio and combining our expertise will enable us to provide even more comprehensive solutions to drug developers facing complex laboratory, manufacturing and other technical challenges globally.”
Bourne Partners served as exclusive financial advisor to Precision for Medicine.
